Compounds and compositions as TLR2 agonists

1. A compound of Formula (I), or pharmaceutically acceptable salt thereof:

wherein:

R 1 is H, —C(O)—C 7 -C 18 alkyl or —C(O)—C 1 -C 6 alkyl;

R 2 is C 7 -C 18 alkyl;

R 3 is C 7 -C 18 alkyl;

L 1 is —CH 2 OC(O)—;

L 2 is —OC(O)—;

R 4 is -L 3 R 5 or -L 4 R 5 ;

R 5 is —P(O)(OR 7 ) 2 , —NR 7 C(O)L 3 R 8 , —NR 7 C(O)L 4 R 8 , —OL 3 R 6 , —C(O)NR 7 L 3 R 8 , —C(O)NR 7 L 4 R 8 , —S(O) 2 OR 7 , —OS(O) 2 OR 7 , C 1 -C 6 alkyl, a C 6 aryl, a C 10 aryl, a C 14 aryl, 5 to 14 ring membered heteroaryl containing 1 to 3 heteroatoms selected from O, S and N, C 3 -C 8 cycloalkyl or a 5 to 6 ring membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, S and N, wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R 5 are each unsubstituted or the aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R 5 are each substituted with 1 to 3 substituents independently selected from —OR 9 , —OL 3 R 6 , —OL 4 R 6 , —OR 7 , and —C(O)OR 7 ;

L 3 is a C 1 -C 10 alkylene, wherein the C 1 -C 10 alkylene of L 3 is substituted with 1 to 4 R 6 groups, or the C 1 -C 10 alkylene of L 3 is substituted with 2 C 1 -C 6 alkyl groups on the same carbon atom which together, along with the carbon atom they are attached to, form a C 3 -C 8 cycloakyl;

L 4 is —((CR 7 R 7 ) p O) q (CR 10 R 10 ) p — or —(CR 11 R 11 )((CR 7 R 7 ) p O) q (CR 10 R 10 ) p —, wherein each R 11 is a C 1 -C 6 alkyl groups which together, along with the carbon atom they are attached to, form a C 3 -C 8 cycloakyl;

each R 6 is independently selected from halo, —OR 7 , —N(R 7 ) 2 , —C(O)N(R 7 ) 2 , —P(O)(OR 7 ) 2 , a C 6 aryl, a C 10 aryl and a C 14 aryl;

each R 7 is independently selected from H and C 1 -C 6 alkyl;

R 8 is —SR 7 , —C(O)OH, —P(O)(OR 7 ) 2 , or a 5 to 6 ring membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O and N;

R 9 is phenyl;

each R 19 is independently selected from H and halo;

each p is independently selected from 1, 2, 3, 4, 5 and 6, and

q is 1, 2, 3 or 4.

2. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R 1 is H.

3. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R 1 is —C(O)—C 15 alkyl.

4. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein:

R 2 is —C 11 alkyl and R 3 is —C 11 alkyl;

or R 2 is —C 10 alkyl and R 3 is —C 10 alkyl;

or R 2 is —C 10 alkyl and R 3 is —C 11 alkyl;

or R 2 is —C 12 alkyl and R 3 is —C 12 alkyl;

or R 2 is —C 7 alkyl and R 3 is —C 7 alkyl;

or R 2 is —C 9 alkyl and R 3 is —C 9 alkyl;

or R 2 is —C 8 alkyl and R 3 is —C 8 alkyl;

or R 2 is —C 13 alkyl and R 3 is —C 13 alkyl;

or R 2 is —C 12 alkyl and R 3 is —C 11 alkyl;

or R 2 is —C 10 alkyl and R 3 is —C 10 alkyl;

or R 2 is —C 15 alkyl and R 3 is —C 15 alkyl.

5. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R 2 is —C 11 alkyl and R 3 is —C 11 alkyl.

6. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R 5 is —P(O)(OH) 2 —S(O) 2 OH, —OS(O) 2 OH, —NHC(O)L 3 R 8 , —OL 3 R 6 , —C(O)NHL 4 R 8 or —C(O)NHL 3 R 8 .

7. The compound of claim 6 , or pharmaceutically acceptable salt thereof, wherein R 5 is —P(O)(OH) 2 —NHC(O)L 3 R 8 , —S(O) 2 OH, —OS(O) 2 OH or —OL 3 R 6 .

8. The compound of claim 1 , wherein R 5 is C 1 -C 6 alkyl, phenyl, pyridinyl, imidazolyl or morpholinyl, each of which is unsubstituted or substituted with 1 to 3 substituents independently selected from —OR 9 , —OL 3 R 6 , —OL 4 R 6 and —OH.

9. The compound of claim 1 , wherein R 8 is —SH, —C(O)OH, —P(O)(OH) 2 , or a 5-6 membered heterocycloalkyl containing 1 to 2 heteroatoms selected from O.

10. The compound of claim 1 , wherein L 3 is a C 1 -C 10 alkylene substituted with 1 to 4 R 6 groups.

11. The compound of claim 1 , wherein:

L 4 is —((CR 7 R 7 ) p O) q (CR 10 R 10 ) p —, each R 10 is independently selected from H and F;

each p is independently selected from 2, 3, and 4, and

q is 1, 2, 3 or 4.

12. The compound of claim 1 , wherein each R 6 is independently selected from —OH, —F, —NH 2 , —C(O)NH 2 , —P(O)(OH) 2 and phenyl.

13. The compound of claim 1 , wherein each R 7 is independently selected from H, methyl and ethyl.

14. The compound of claim 1 , wherein the compound is selected from:

(R)-3-(((R)-2-amino-3-((1-(hydroxymethyl)cyclopropyl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(3-((R)-2-amino-3-(((R)-2,3-bis(dodecanoyloxy)propyl)thio)propanamido)propyl)phosphonic acid;

((8R,12R)-8-amino-12-(dodecanoyloxy)-7,15-dioxo-3,14-dioxa-10-thia-6-azahexacosyl)phosphonic acid;

((12R,16R)-12-amino-16-(dodecanoyloxy)-1,1-difluoro-11,19-dioxo-4,7,18-trioxa-14-thia-10-azatriacontyl)phosphonic acid;

((11R,15R)-11-amino-15-(dodecanoyloxy)-10,18-dioxo-3,6,17-trioxa-13-thia-9-azanonacosyl)phosphonic acid;

(R)-3-(((R)-2-amino-3-oxo-3-((2-(pyridin-2-yl)ethyl)amino)propyl)thio)propane-1,2-diyl didodecanoate;

(20R,24R)-2,20-diamino-1-mercapto-3,19-dioxo-8,11,14-trioxa-22-thia-4,18-diazapentacosane-24,25-diyl didodecanoate;

((6S,9R,13R)-9-amino-13-(dodecanoyloxy)-6-methyl-8,16-dioxo-4,15-dioxa-11-thia-7-azaheptacosyl)phosphonic acid;

(3-((1-((R)-2-amino-3-(((R)-2,3-bis(dodecanoyloxy)propyl)thio)propanamido)cyclopropyl)methoxy)propyl)phosphonic acid;

(3-(4-(2-((R)-2-amino-3-(((R)-2,3-bis(dodecanoyloxy)propyl)thio)propanamido)ethyl)phenoxy)propyl)phosphonic acid;

((14R,18R)-14-amino-18-(dodecanoyloxy)-13,21-dioxo-3,6,9,20-tetraoxa-16-thia-12-azadotriacontyl)phosphonic acid;

(4-((R)-2-amino-3-(((R)-2,3-bis(dodecanoyloxy)propyl)thio)propanamido)-1,1-difluorobutyl)phosphonic acid;

((9R,13R)-9-amino-13-(dodecanoyloxy)-1,1-difluoro-8,16-dioxo-4,15-dioxa-11-thia-7-azaheptacosyl)phosphonic acid;

((14R,18R)-14-amino-18-(octanoyloxy)-13,21-dioxo-3,6,9,20-tetraoxa-16-thia-12-azaoctacosyl)phosphonic acid;

((14R,18R)-14-amino-18-(decanoyloxy)-13,21-dioxo-3,6,9,20-tetraoxa-16-thia-12-azatriacontyl)phosphonic acid;

((14R,18R)-14-amino-13,21-dioxo-18-(tetradecanoyloxy)-3,6,9,20-tetraoxa-16-thia-12-azatetratriacontyl)phosphonic acid;

((14R,18R)-18-(dodecanoyloxy)-13,21-dioxo-14-palmitamido-3,6,9,20-tetraoxa-16-thia-12-azadotriacontyl)phosphonic acid;

(20R,24R)-1-(1,3-dioxolan-2-yl)-3,19-dioxo-20-palmitamido-8,11,14-trioxa-22-thia-4,18-diazapentacosane-24,25-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-((4-(2-(2-hydroxyethoxy)ethoxy)phenethyl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-((4-(isopentyloxy)phenethyl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-((3-hydroxyphenethyl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-((4-hydroxyphenethyl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-oxo-3-(phenethylamino)propyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-oxo-3-((2-(pyridin-4-yl)ethyl)amino)propyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-((3-morpholinopropyl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-3-((3-(1H-imidazol-1-yl)propyl)amino)-2-amino-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-oxo-3-((2-(pyridin-3-yl)ethyl)amino)propyl)thio)propane-1,2-diyl didodecanoate;

(2R)-3-(((2R)-2-amino-3-((1,2-diphenylethyl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-oxo-3-((4-phenoxyphenethyl)amino)propyl)thio)propane-1,2-diyl didodecanoate;

((14R,18R)-14-amino-18-(hexadecyloxy)-13-oxo-3,6,9,20-tetraoxa-16-thia-12-azahexatriacontyl)phosphonic acid;

((17R,21R)-17-amino-21-(dodecanoyloxy)-16,24-dioxo-3,6,9,12,23-pentaoxa-19-thia-15-azapentatriacontyl)phosphonic acid;

3-((R)-2-amino-3-(((R)-2,3-bis(dodecanoyloxy)propyl)thio)propanamido)propane-1-sulfonic acid; and

(R)-3-(((R)-2-amino-3-oxo-3-((2-(2-(sulfooxy)ethoxy)ethyl)amino)propyl)thio)propane-1,2-diyldidodecanoate.

15. A compound selected from:

(R)-3-(((R)-2-amino-3-((5-aminopentyl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(2R,6R)-6,20-diamino-7-oxo-12,17-dioxa-4-thia-8-azaicosane-1,2-diyl didodecanoate;

(5S,8R,12R)-8-amino-12-(dodecanoyloxy)-5-ethyl-7,15-dioxo-3,14-dioxa-10-thia-6-azahexacosan-1-oic acid;

6-((R)-2-amino-3-(((R)-2,3-bis(dodecanoyloxy)propyl)thio)propanamido)hexanoic acid;

10-((R)-2-amino-3-(((R)-2,3-bis(dodecanoyloxy)propyl)thio)propanamido)decanoic acid;

(R)-3-(((R)-2-amino-3-((1-hydroxy-2-methylpropan-2-yl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-(((R)-1-hydroxypropan-2-yl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-(((S)-1-hydroxypropan-2-yl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(4R,7S,10R,14R)-4-carbamoyl-7-ethyl-6,9,17-trioxo-10-palmitamido-14-(palmitoyloxy)-16-oxa-12-thia-5,8-diazadotriacontan-1-oic acid;

(4R,7S,10R,14R)-10-amino-4-carbamoyl-7-ethyl-6,9,17-trioxo-14-(palmitoyloxy)-16-oxa-12-thia-5,8-diazadotriacontan-1-oic acid;

(2R)-3-(((2R)-2-amino-3-((1-(4-hydroxyphenyl)ethyl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(2R)-3-(((2R)-2-amino-3-oxo-3-((1-phenylethyl)amino)propyl)thio)propane-1,2-diyl didodecanoate;

(11R,15R)-1,11-diamino-10-oxo-3,6-dioxa-13-thia-9-azahexadecane-15,16-diyl didodecanoate;

(R)-3-4(R)-2-amino-3-((2-aminoethyl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-((6-aminohexyl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-((4-aminobutyl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-((3-aminopropyl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(2R)-3-(((2R)-2-amino-3-((1-methoxybutan-2-yl)amino)-3-oxopropyl)thio)propane-1,2-diyldidodecanoate;

(16R,20R)-1,16-diamino-15-oxo-4,7,10-trioxa-18-thia-14-azahenicosane-20,21-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-(((1R,2S)-1-hydroxy-1-phenylpropan-2-yl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(2R)-3-(((2R)-2-amino-3-oxo-3-((4-phenylbutan-2-yl)amino)propyl)thio)propane-1,2-diyl didodecanoate;

(2R)-3-(((2R)-2-amino-3-((5-(diethylamino)pentan-2-yl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-((6-hydroxyhexyl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-((2-hydroxyethyl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(R)-3-(((R)-2-amino-3-((5-hydroxy-4,4-dimethylpentyl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(2R)-3-(((2R)-2-amino-3-oxo-3-((2-phenylpropyl)amino)propyl)thio)propane-1,2-diyl didodecanoate;

(2R)-3-(((2R)-2-amino-3-((5-methylhexan-2-yl)amino)-3-oxopropyl)thio)propane-1,2-diyl didodecanoate;

(4R,7S,10R,14R)-4-carbamoyl-14-(dodecanoyloxy)-7-methyl-6,9,17-trioxo-10-palmitamido-16-oxa-12-thia-5,8-diazaoctacosan-1-oic acid;

(15R,19R)-15-amino-19-(dodecanoyloxy)-14,22-dioxo-4,7,10,21-tetraoxa-17-thia-13-azatritriacontan-1-oic acid;

(15R,19R)-19-(dodecanoyloxy)-14,22-dioxo-15-palmitamido-4,7,10,21-tetraoxa-17-thia-13-azatritriacontan-1-oic acid;

(15S,18R,22R)-18-amino-22-(dodecanoyloxy)-15-(hydroxymethyl)-14,17,25-trioxo-4,7,10,24-tetraoxa-20-thia-13,16-diazahexatriacontan-1-oic acid;

(15S,18R,22R)-22-(dodecanoyloxy)-15-(hydroxymethyl)-14,17,25-trioxo-18-palmitamido-4,7,10,24-tetraoxa-20-thia-13,16-diazahexatriacontan-1-oic acid;

((17R,21R)-17-amino-21-(dodecyloxy)-16-oxo-3,6,9,12,23-pentaoxa-19-thia-15-azapentatriacontyl)phosphonic acid;

((17R,21R)-17-amino-21-dodecanamido-16-oxo-3,6,9,12,23-pentaoxa-19-thia-15-azapentatriacontyl)phosphonic acid;

((11S,14R,18R)-14-amino-18-(dodecyloxy)-11-(hydroxymethyl)-10,13-dioxo-3,6,20-trioxa-16-thia-9,12-diazadotriacontyl)phosphonic acid;

((11S,14R,18R)-14-amino-18-dodecanamido-11-(hydroxymethyl)-10,13-dioxo-3,6,20-trioxa-16-thia-9,12-diazadotriacontyl)phosphonic acid, and

((14R,18R)-14-amino-18-((decylcarbamoyl)oxy)-13,21-dioxo-3,6,9,20-tetraoxa-16-thia-12,22-diazadotriacontyl)phosphonic acid.

16. A pharmaceutical composition comprising a therapeutically effective amount a compound of claim 1 and a pharmaceutically acceptable carrier.

17. A method for treating a disease where modulation of TLR2 receptor is implicated, wherein the method comprises administering to a system or subject in need of such treatment an effective amount of a compound of claim 1 , wherein the compound of Formula (I) is a TLR2 receptor agonist and the disease is selected from an infectious disease, an inflammatory disease, a respiratory disease, a dermatological disease and an autoimmune disease.

18. The method of claim 17 , wherein the disease is asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), ulcerative colitis, Crohns disease, bronchitis, dermatitis, actinic keratosis, basal cell carcinoma, allergic rhinitis, psoriasis, scleroderma, urticaria, rheumatoid arthritis, multiple sclerosis, cancer, breast cancer, HIV or lupus.